Proportion of Clinical Improvement and Score Comparison of Type 1 Interferon, Transcriptomic Analysis in Idiopathic Uveitis Patients With IGRA Positive Before and After Anti-Tuberculosis Drugs Treatment: Cohort Prospective Study
The aim of this study is to determine the proportion of clinical improvement, the score changing of type 1 interferon selected gene expression, and analysis of transcriptomics profiling in patients with idiopathic uveitis positive IGRA before and after receiving Anti-Tuberculosis Therapy (ATT). Hopefully, by conducting this research, we are able to provide valid data that demonstrate the advantages/disadvantages usage of Anti-Tuberculosis Therapy in patients with idiopathic uveitis IGRA positive that correlate with type I IFN. This research is a part of our efforts in discovering bio-marker candidates of idiopathic uveitis IGRA positive clinical patients who will benefit from the ATT administration.
∙ Subjects who will be recruited to this study are patients who met the criteria described below:
• Registered patients from September 2019 at Cipto Mangunkusumo Hospital
• Idiopathic uveitis patients (proven having negative result by available etiological uveitis work-ups) with IGRA positive. IGRA positive value is defined by score above 0.35 u/ml obtained from Quantiferon Tuberculosis (QFT)-Gold Assay (QIAGEN).
• Minimum age: 18 years old
• Proven not having active Tuberculosis
• Not previously received Anti Tuberculosis Therapy.
• Not consuming antibiotic one to two weeks prior to the time of study
• Not living together with Tuberculosis active patient
• Not having plan to become pregnant during the time of study
• Not part of reactive Tuberculosis risk group based on Latent Tuberculosis Incident WHO guidelines 2018
• Active inflammation in the past 180 days characterized by the following sign based on SUN Criteria(in at least one eye)
‣ ≥ 2+ anterior chamber cells
⁃ ≥ 2+ vitreous haze
⁃ active retinal or choroidal lesions
• Active inflammation during patient registration, characterized by the following sign based on SUN Criteria (in at least one eye)
‣ ≥1+ anterior chamber cells and/or
⁃ ≥1+ vitreous haze and/or
⁃ active retinal/choroidal lesions